COCRYSTAL PHARMA, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
COCRYSTAL PHARMA, INC. (COCP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $92.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $92.00K, a 9.52% increase year-over-year.
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $84.00K, a 2.44% increase year-over-year.
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $48.00K, a 80.95% decline year-over-year.
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $84.00K, a 43.24% decline year-over-year.
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $270.00K, a 58.01% decline from fiscal 2024.
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $643.00K, a 19.73% decline from fiscal 2023.
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $801.00K, a 6.32% decline from fiscal 2022.
- COCRYSTAL PHARMA, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $855.00K, a 18.09% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $92.00K 10-Q · filed 2026-08-13 | $176.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $84.00K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $270.00K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $48.00K 10-Q · filed 2025-11-14 | $132.00K derived: sum of 2 quarters · filed 2026-08-13 | $214.00K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $84.00K 10-Q · filed 2026-08-13 | $166.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $82.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $643.00K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $252.00K 10-Q · filed 2025-11-14 | $400.00K derived: sum of 2 quarters · filed 2025-11-14 | $557.00K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $148.00K 10-Q · filed 2025-11-14 | $305.00K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $157.00K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $801.00K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $173.00K 10-Q · filed 2024-11-13 | $352.00K derived: sum of 2 quarters · filed 2024-11-13 | $643.00K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $179.00K 10-Q · filed 2024-11-13 | $470.00K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $291.00K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $855.00K 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $216.00K 10-Q · filed 2023-11-13 | $457.00K derived: sum of 2 quarters · filed 2023-11-13 | $696.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $241.00K 10-Q · filed 2023-11-13 | $480.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $239.00K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $724.00K 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $205.00K 10-Q · filed 2022-11-14 | $283.00K derived: sum of 2 quarters · filed 2022-11-14 | $502.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $78.00K 10-Q · filed 2022-11-14 | $297.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $219.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $662.00K 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $237.00K 10-Q · filed 2021-11-15 | $356.00K derived: sum of 2 quarters · filed 2021-11-15 | $463.00K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $119.00K 10-Q · filed 2021-11-15 | $226.00K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $107.00K 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $351.00K 10-K · filed 2021-03-17 | |||
| 2019-09-30 | $107.00K 10-Q · filed 2020-11-13 | $220.00K derived: sum of 2 quarters · filed 2020-11-13 | $253.00K derived: sum of 3 quarters · filed 2020-11-13 | $483.00K derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $113.00K 10-Q · filed 2020-11-13 | $146.00K derived: sum of 2 quarters · filed 2020-11-13 | $376.00K derived: sum of 3 quarters · filed 2020-11-13 | $496.00K derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-03-31 | $33.00K 10-Q · filed 2020-11-13 | $263.00K derived: sum of 2 quarters · filed 2020-11-13 | $383.00K derived: sum of 3 quarters · filed 2020-11-13 | $490.00K derived: sum of 4 quarters · filed 2020-11-13 |
| 2018-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $350.00K derived: sum of 2 quarters · filed 2020-03-27 | $457.00K derived: sum of 3 quarters · filed 2020-03-27 | $562.00K 10-K · filed 2020-03-27 |
| 2018-09-30 | $120.00K 10-Q · filed 2019-11-12 | $227.00K derived: sum of 2 quarters · filed 2019-11-12 | $332.00K 10-Q · filed 2018-11-09 | $537.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $107.00K 10-Q · filed 2019-11-12 | $212.00K 10-Q · filed 2018-08-09 | $417.00K derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-03-31 | $105.00K 10-Q · filed 2019-11-12 | $310.00K derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2017-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $614.00K 10-K · filed 2019-04-01 | ||
| 2017-09-30 | $409.00K 10-Q · filed 2017-11-08 | |||
| 2016-12-31 | $548.00K 10-K · filed 2018-03-21 | |||
| 2015-12-31 | $2.93M 10-K · filed 2018-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |